Piper Sandler Initiates UroGen Pharma Coverage at Overweight with PT $36

Piper Sandler Initiates UroGen Pharma Coverage at Overweight with PT $36

Piper Sandler has initiated coverage on UroGen Pharma Ltd. with an overweight rating and a price target of $36. The biopharmaceutical company is based in Israel and specializes in developing solutions for cancers and urologic diseases. UroGen has developed RTGel™, a proprietary sustained release, hydrogel-based platform technology that enhances the therapeutic profiles of existing drugs.

The company's lead product candidates, MitoGel and VesiGel, are formulated using the RTGel technology. MitoGel (UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma. VesiGel (UGN-102) is a sustained release formulation of high-dose Mitomycin C for the treatment of low-grade non-muscle invasive bladder cancer (LG-NMIBC).

Piper Sandler's analysis suggests that UroGen Pharma's pipeline and technology have significant potential in the market. The firm believes that the company's innovative approach to drug delivery could lead to improved patient outcomes and increased market share.

References:
[1] https://www.marketscreener.com/news/piper-sandler-initiates-urogen-pharma-at-overweight-with-36-price-target-ce7c51ddd981f421